Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature.

导出 LinkOut

翻译打印收藏纠错

作者： Arsela,Prelaj ^[1] ; Sara Elena,Rebuzzi ^[2] ; Massimiliano,Grassi ^[2] ; Maurizio,Salvati ^[3] ; Alessandro,D'Elia ^[3] ; Francesca,Buttarelli ^[4] ; Carla,Ferrara ^[5] ; Silverio,Tomao ^[1] ; Vincenzo,Bianco ^[1]

作者单位： Department of Radiological, Oncological and Anatomo-Pathological Sciences, 'Sapienza' University of Rome, Policlinico Umberto I, I-00161 Rome, Italy. ^[1] Department of Medical Oncology, Ospedale Policlinico San Martino IST, University of Genoa, I-16132 Genoa, Italy. ^[2] Neurosurgery Department, IRCCS NEUROMED INM, Neurochirurgia, I-86077 Pozzilli, Italy. ^[3] Department of Neurology and Psychiatry 'Sapienza' University of Rome, Policlinico Umberto I, I-00161 Rome, Italy. ^[4] Department of Public Health and Infectious Diseases, 'Sapienza' University of Rome, I-00185 Rome, Italy. ^[5]

关键词 MGMT fotemustine irradiation recurrent glioblastoma recurrent malignant glioma second-line surgery

DOI 10.3892/mco.2018.1746

PMID 30655978

发布时间 2020-09-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览6

Molecular and clinical oncology

2019年10卷1期

58-66页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature.

Molecular and clinical oncology

相似文献

Molecular and clinical oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature.

Molecular and clinical oncology

相似文献

Molecular and clinical oncology

相关期刊

检索历史清除